Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4
Journal Title
ChemMedChem
Publication Type
30 Aug epub ahead of print
Abstract
The emergence of resistance against current antimalarial treatments has necessitated the need for the development of novel antimalarial chemotypes. Toward this goal, we recently optimised the antimalarial activity of the dihydroquinazolinone scaffold and showed it targeted PfATP4. Here, we deconstruct the lactam moiety of the tricyclic dihydroquinazolinone scaffold and investigate the structure-activity relationship of the truncated scaffold. It was shown that SAR between scaffolds was largely transferrable and generated analogues with potent asexual stage activity. Evaluation of the truncated analogues against PfATP4 mutant drug resistant parasite strains and in assays measuring PfATP4-associated ATPase activity demonstrated retention of PfATP4 as the molecular target. Analogues exhibited activity against both male and female gametes and multidrug resistant parasites. Limited efficacy of analogues in a P. berghei asexual stage mouse model was attributed to their moderate metabolic stability and low aqueous stability. Further development is required to address these attributes toward the potential use of the dihydroquinazolinone class in a curative and transmission blocking combination antimalarial therapy.
Publisher
Wiley
Keywords
antimalarial, Malaria, PfATP4, Plasmodium, quinazolinone
Research Division(s)
Chemical Biology; Advanced Technology and Biology; Structural Biology; Infectious Diseases and Immune Defence
PubMed ID
39210733
Open Access at Publisher's Site
https://doi.org/10.1002/cmdc.202400549
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-02 10:41:58
Last Modified: 2024-09-02 10:54:59
An error has occurred. This application may no longer respond until reloaded. Reload 🗙